Bosh sahifaABCL • NASDAQ
add
AbCellera Biologics Inc
2,44 $
Seans yopilganidan keyin:(0,00%)0,00
2,44 $
Yopilgan:6-iyn, 19:55:15 (GMT-4) · USD · NASDAQ · Ogohlantirish
Yopilish kursi
2,37 $
Kunlik diapazon
2,38 $ - 2,49 $
Yillik diapazon
1,89 $ - 3,76 $
Bozor kapitalizatsiyasi
728,30 mln USD
Oʻrtacha hajm
3,98 mln
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | 4,24 mln | -57,45% |
Joriy xarajat | 24,40 mln | -4,55% |
Sof foyda | -45,62 mln | -12,34% |
Sof foyda marjasi | -1,08 ming | -164,04% |
Har bir ulushga tushum | -0,15 | -7,14% |
EBITDA | -57,33 mln | -14,54% |
Amaldagi soliq stavkasi | 13,90% | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 605,27 mln | -13,29% |
Jami aktivlari | 1,34 mlrd | -8,13% |
Jami passivlari | 321,23 mln | -3,59% |
Umumiy kapital | 1,02 mlrd | — |
Tarqatilgan aksiyalar | 298,48 mln | — |
Narxi/balansdagi bahosi | 0,69 | — |
Aktivlardan daromad | -11,58% | — |
Kapitaldan daromad | -14,16% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -45,62 mln | -12,34% |
Operatsiyalardan naqd pul | -11,55 mln | 72,30% |
Sarmoyadan naqd pul | 7,94 mln | -73,47% |
Moliyadan naqd pul | 5,97 mln | 110,88% |
Naqd pulning sof oʻzgarishi | 2,94 mln | 130,17% |
Boʻsh pul | -63,60 mln | -21,59% |
Haqida
AbCellera Biologics Inc. is a Vancouver, British Columbia-based contract research organization that is contracted by biotechnology and pharmaceutical companies for antibody services, and researches and develops human antibodies as a service for its clients. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia. Wikipedia
CEO
Tashkil etilgan
2012
Sayt
Xodimlar soni
596
